Quest Partners LLC Takes Position in Fulcrum Therapeutics, Inc. (NASDAQ:FULC)

Quest Partners LLC bought a new stake in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 26,164 shares of the company’s stock, valued at approximately $162,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. National Bank of Canada FI grew its stake in shares of Fulcrum Therapeutics by 869.6% in the second quarter. National Bank of Canada FI now owns 4,460 shares of the company’s stock valued at $28,000 after buying an additional 4,000 shares in the last quarter. Capstone Investment Advisors LLC purchased a new position in shares of Fulcrum Therapeutics in the fourth quarter valued at approximately $68,000. China Universal Asset Management Co. Ltd. grew its holdings in shares of Fulcrum Therapeutics by 66.7% in the first quarter. China Universal Asset Management Co. Ltd. now owns 11,916 shares of the company’s stock valued at $112,000 after purchasing an additional 4,766 shares in the last quarter. SG Americas Securities LLC purchased a new stake in Fulcrum Therapeutics during the 1st quarter worth approximately $115,000. Finally, Los Angeles Capital Management LLC acquired a new stake in Fulcrum Therapeutics during the 2nd quarter worth approximately $130,000. Hedge funds and other institutional investors own 89.83% of the company’s stock.

Fulcrum Therapeutics Stock Performance

FULC opened at $3.18 on Monday. Fulcrum Therapeutics, Inc. has a one year low of $2.87 and a one year high of $13.70. The stock has a market capitalization of $197.65 million, a P/E ratio of -1.99 and a beta of 2.23. The business’s 50-day simple moving average is $8.41 and its 200-day simple moving average is $8.26.

Fulcrum Therapeutics (NASDAQ:FULC) last issued its quarterly earnings data on Wednesday, July 31st. The company reported $0.87 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.93. The company had revenue of $80.00 million during the quarter, compared to analysts’ expectations of $80.00 million. Fulcrum Therapeutics had a negative return on equity of 8.28% and a negative net margin of 3,470.05%. During the same quarter in the previous year, the business earned ($0.38) earnings per share. On average, equities research analysts forecast that Fulcrum Therapeutics, Inc. will post -0.48 EPS for the current fiscal year.

Analyst Ratings Changes

FULC has been the topic of a number of recent research reports. Royal Bank of Canada lowered Fulcrum Therapeutics from an “outperform” rating to a “sector perform” rating and cut their price objective for the stock from $15.00 to $4.00 in a research report on Thursday. Stifel Nicolaus cut Fulcrum Therapeutics from a “buy” rating to a “hold” rating and decreased their price objective for the company from $22.00 to $3.00 in a research note on Thursday. Cantor Fitzgerald lowered shares of Fulcrum Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Thursday. Leerink Partnrs cut shares of Fulcrum Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday. Finally, HC Wainwright lowered shares of Fulcrum Therapeutics from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $17.00 to $4.00 in a report on Friday. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and three have given a buy rating to the company. According to MarketBeat, Fulcrum Therapeutics has a consensus rating of “Hold” and a consensus price target of $9.33.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.